title: Opsoclonus-myoclonus in children associated or not with neuroblastoma.
abstract: OBJECTIVE
  To compare the clinical data at diagnosis, treatment and neurological outcome in 34 children with opsoclonus-myoclonus syndrome (OMS) associated with a detected neuroblastoma or not.
  
  
  METHODS
  This is a multicentric retrospective study of 34 children presenting with OMS from four pediatric centers diagnosed between 1988 and 2008.
  
  
  RESULTS
  Twenty-two patients had OMS associated with a neuroblastoma. These patients all had neuroblastomas with favourable prognostic features; all underwent surgery, six received chemotherapy. Twelve children had OMS without a detected neuroblastoma. For OMS, the main treatment in all children was corticotherapy (n=33), but immunoglobulins (n=13), cyclophosphamide (n=4) and rituximab (n=4) were also given. In the 27 OMS patients with or without neuroblastoma whose follow up was greater than two years, the neurological outcome was evaluated: 59.3% had neurological sequelae, including motor, praxic and/or language sequelae (n=9), persistent ataxia (n=6) and moderate motor deficit (n=3). No significant difference in neurological outcome was noted between the two patient groups.
  
  
  CONCLUSIONS
  Our retrospective study provides further evidence that OMS with or without a detected neuroblastoma is the same disease, whose major challenges are the neurological sequelae. An international collaboration is required to improve the knowledge about OMS, the treatment and the outcome in this rare disorder.
authors.affiliation: Pediatric Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Krug
authors.forename: Gudrun
authors.initials: G
authors.lastname: Schleiermacher
authors.forename: Jean
authors.initials: J
authors.lastname: Michon
authors.forename: Dominique
authors.initials: D
authors.lastname: Valteau-Couanet
authors.forename: Hervé
authors.initials: H
authors.lastname: Brisse
authors.forename: Michel
authors.initials: M
authors.lastname: Peuchmaur
authors.forename: Sabine
authors.initials: S
authors.lastname: Sarnacki
authors.forename: Hélène
authors.initials: H
authors.lastname: Martelli
authors.forename: Isabelle
authors.initials: I
authors.lastname: Desguerre
authors.forename: Marc
authors.initials: M
authors.lastname: Tardieu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000150:complications*; D053578:Opsoclonus-Myoclonus Syndrome / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D012189:Retrospective Studies
chemical_list: D000305:Adrenal Cortex Hormones